Burzynski Research Institute Reports Decreased Net Loss and Increased Current Assets

Burzynski Research Institute, Inc. reported its financial results for the three and nine months ended November 30, 2025, revealing a net loss of approximately $328,862 for the quarter, a decrease from a loss of $352,239 in the same period last year. For the nine-month period, the net loss was $994,180, down from $1,093,409 in the prior year. The company’s total operating expenses for the quarter were $328,862, a reduction from $352,239 in the previous year, primarily due to decreased research and development costs, which fell to $260,800 from $301,183. General and administrative expenses increased by 33% to $68,062, attributed to higher professional fees and regulatory costs.

The company’s financial position showed significant changes compared to the previous fiscal period. Total current assets increased to $2,265,000 from $847,000, while total liabilities rose to $69,608,000 from $42,484,000. This resulted in a working capital deficit of $67,343,000, worsening from a deficit of $41,637,000 as of February 28, 2025. The increase in liabilities was largely due to a rise in accounts payable, which grew to $45,101,000 from $17,017,000, reflecting ongoing operational challenges.

Strategically, Burzynski Research Institute has continued its focus on research and development of Antineoplaston drugs for cancer treatment, although its investigational new drug application remains under full clinical hold by the FDA. The company has entered into a new licensing agreement with Dr. S.R. Burzynski, which grants exclusive rights to develop and market Antineoplastons in the U.S. and Canada. This agreement is crucial as it allows the company to potentially exploit new patents related to its drug development efforts, although actual commercialization remains contingent on FDA approval.

Operationally, the company has not reported significant revenue generation, relying heavily on funding from Dr. Burzynski’s medical practice. The total cash at the end of the reporting period was $2,165,000, a slight increase from $847,000 at the beginning of the period. The company’s ability to continue operations is heavily dependent on Dr. Burzynski’s financial support, as indicated by the ongoing Research Funding Agreement, which has been extended until February 28, 2026. The company anticipates needing approximately $300,000 for the remaining quarter of the fiscal year, but there is no assurance that funding will continue at the same level.

Looking ahead, Burzynski Research Institute faces significant uncertainty regarding its future operations and financial stability. The company has indicated that it may need to seek additional capital through equity or debt financing, or asset sales, to sustain its operations. The management has expressed concerns about the ability to achieve positive cash flow and profitability, given the ongoing clinical hold and the lack of significant revenue. The company’s future remains contingent on the successful resolution of regulatory issues and the ability to secure necessary funding.